Chikungunya vaccine safety checked in pregnant women
NCT ID NCT07414524
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study follows 200 pregnant women in Brazil who received the chikungunya vaccine (VLA1553) during pregnancy or shortly before. Researchers will track pregnancy and infant health up to 12 weeks after birth, comparing them to a similar group of women who got routine vaccines. The goal is to see if the vaccine is safe for both mother and baby.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Live-attenuated chikungunya virus vaccine (VLA1553)
What this could lead to
If successful, this study could provide important safety data on the chikungunya vaccine for pregnant women, helping guide vaccination recommendations.
What could go wrong
This is an observational study, not a controlled trial, so results may be influenced by other factors. The study is small (200 participants) and only looks at short-term outcomes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHIKUNGUNYA VIRUS INFECTION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••